These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 15137473

  • 1. Appropriate outpatient macrolide use in community-acquired pneumonia.
    Gotfried MH.
    J Am Acad Nurse Pract; 2004 Apr; 16(4):146, 148, 150 passim. PubMed ID: 15137473
    [Abstract] [Full Text] [Related]

  • 2. International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.
    File TM, Tan JS.
    Drugs; 2003 Apr; 63(2):181-205. PubMed ID: 12515565
    [Abstract] [Full Text] [Related]

  • 3. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
    File TM.
    J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S5-11. PubMed ID: 19236135
    [Abstract] [Full Text] [Related]

  • 4. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X, Sikirica V, Schein JR, Grant R, Zarotsky V, Doshi D, Benson CJ, Riedel AA.
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [Abstract] [Full Text] [Related]

  • 5. Macrolide Resistance in Cases of Community-Acquired Bacterial Pneumonia in the Emergency Department.
    Haran JP, Volturo GA.
    J Emerg Med; 2018 Sep; 55(3):347-353. PubMed ID: 29789175
    [Abstract] [Full Text] [Related]

  • 6. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
    Weiss K, Tillotson GS.
    Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
    [Abstract] [Full Text] [Related]

  • 7. Community-acquired pneumonia: the evolving challenge.
    Finch R.
    Clin Microbiol Infect; 2001 Aug; 7 Suppl 3():30-8. PubMed ID: 11523560
    [Abstract] [Full Text] [Related]

  • 8. Current treatment of community-acquired pneumonia.
    Liapikou A, Torres A.
    Expert Opin Pharmacother; 2013 Jul; 14(10):1319-32. PubMed ID: 23663104
    [Abstract] [Full Text] [Related]

  • 9. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia.
    File TM, Garau J, Blasi F, Chidiac C, Klugman K, Lode H, Lonks JR, Mandell L, Ramirez J, Yu V.
    Chest; 2004 May; 125(5):1888-901. PubMed ID: 15136404
    [Abstract] [Full Text] [Related]

  • 10. Diagnosis and management of community-acquired pneumonia in adults.
    Watkins RR, Lemonovich TL.
    Am Fam Physician; 2011 Jun 01; 83(11):1299-306. PubMed ID: 21661712
    [Abstract] [Full Text] [Related]

  • 11. Empiric therapy of community-acquired pneumonia: guidelines for the perplexed?
    Cunha BA.
    Chest; 2004 May 01; 125(5):1913-9. PubMed ID: 15136407
    [Abstract] [Full Text] [Related]

  • 12. Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.
    Epstein BJ, Gums JG.
    Drugs; 2005 May 01; 65(14):1949-71. PubMed ID: 16162020
    [Abstract] [Full Text] [Related]

  • 13. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.
    Eljaaly K, Alshehri S, Aljabri A, Abraham I, Al Mohajer M, Kalil AC, Nix DE.
    BMC Infect Dis; 2017 Jun 02; 17(1):385. PubMed ID: 28576117
    [Abstract] [Full Text] [Related]

  • 14. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
    Raz-Pasteur A, Shasha D, Paul M.
    Int J Antimicrob Agents; 2015 Sep 02; 46(3):242-8. PubMed ID: 26092096
    [Abstract] [Full Text] [Related]

  • 15. Treatment of community-acquired pneumonia--IDSA guidelines. Infectious Diseases Society of America.
    Bernstein JM.
    Chest; 1999 Mar 02; 115(3 Suppl):9S-13S. PubMed ID: 10084453
    [Abstract] [Full Text] [Related]

  • 16. Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices.
    Bartlett JG.
    Semin Respir Infect; 1997 Dec 02; 12(4):329-33. PubMed ID: 9436960
    [Abstract] [Full Text] [Related]

  • 17. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
    Segreti J, House HR, Siegel RE.
    Am J Med; 2005 Jul 02; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial therapy of community-acquired pneumonia.
    File TM, Niederman MS.
    Infect Dis Clin North Am; 2004 Dec 02; 18(4):993-1016, xi. PubMed ID: 15555836
    [Abstract] [Full Text] [Related]

  • 19. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters.
    Piso RJ, Arnold C, Bassetti S.
    Swiss Med Wkly; 2013 Dec 02; 143():w13870. PubMed ID: 24089030
    [Abstract] [Full Text] [Related]

  • 20. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.
    Charles PG, Whitby M, Fuller AJ, Stirling R, Wright AA, Korman TM, Holmes PW, Christiansen KJ, Waterer GW, Pierce RJ, Mayall BC, Armstrong JG, Catton MG, Nimmo GR, Johnson B, Hooy M, Grayson ML, Australian CAP Study Collaboration.
    Clin Infect Dis; 2008 May 15; 46(10):1513-21. PubMed ID: 18419484
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.